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Detection of circulating tumor cells (CTCs) in blood has been rapidly developing into a 
promising early cancer diagnostic tool. CTCs provide crucial evidence of the progression and 
status of the disease. Early cancer detection provides a powerful prevention step, allowing for 
effective treatment. This thesis presents an efficient method for cancer cell capture via cell line-
specific antibody deposition and adsorption on nanoporous silica substrates using a method 
called “micro-contact printing” and immunofluorescence detection through quantum dot labeling 
within a microfluidic system.  
Microcontact printing is essential in efficient design, characterization, and production of 
biologics for cost effective, high throughput, and point-of-care detection and analysis system. 
Nanoporous silica enhances the adsorption of proteins onto its surface. Quantum dots enable 
brighter and more stable fluorescence imaging of biological species. Additionally, microfluidic 
systems allow for more effective antibody-antigen interactions due to physical dimensional 
constraints of the microfluidic channel itself, forcing closer proximities between antigen and 
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antibody, thus increasing binding probabilities. Coupled together, a compact system for efficient 
and effective microchip-based diagnostics and detection can be designed.  
Such a system sets the stage for a versatile platform capable of single cell based analyses 
including manipulation, sensing and imaging for different biomedical applications. Within a 
single biosensing platform, it integrates multiple functions such as multiplexing and multicolor 
detection capabilities. Each component of the platform plays an important role in enhancing the 
sensitivity and specificity. The proposed research shows great promise for potential applications 
in high throughput screening and drug assays, cellular biomarker studies, site-specific cell 
culturing in microarrays and cancer cell detection.  
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 1 Introduction 
 
1.1 Background and Motivation 
1.1.1 Cancer Metastasis 
 
Cancer is a condition in which the body experiences uncontrolled growth of abnormal 
cells. Cancer cells originate from normal cells in the body that hyperactively divide at a rapid 
rate due to genetic mutations in the cells’ deoxyribonucleic acid (DNA) [1]. Many different types 
of cancer exist and can be caused or triggered by various genetic or environmental factors, such 
as tobacco smoking, diet and physical activity, and sun or UV exposure [2]. As one of the 
leading causes of death, cancer is the cause of about 13% of all deaths in 2008 [3].  
One of the primary reasons why cancer has been deemed such a malignant and potent 
disease is due to its ability to spread to other parts of the body and become metastatic. 
Circulating tumor cells (CTCs) are tumor cells that have detached from the primary tumor site 
and are circulating in the patient’s peripheral circulatory system or lymphatic system [4]. CTCs 
travel to and lodge themselves at secondary tumor sites. There, they remain dormant until 
triggered by specific complex cellular signals, wherein they begin to metastasize, growing and 
developing into a secondary cancerous tumor. 
Therefore, it has become exceedingly important to be capable of detecting and 
diagnosing the disease in its early stages before further metastasis and deterioration of patient 
health occur. Early cancer diagnostics is the most powerful prevention step, preventing spread of 
the disease beyond the already affected area by allowing for earlier and easier treatment. It also 
provides the motivation behind the cancer detection system presented in this thesis.  
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1.1.2 Early Diagnostics and Detection 
 
 Conventional detection and diagnosis of cancer includes tumor biopsy, bone marrow 
biopsy, computed tomography (CT) scans, and magnetic resonance imaging (MRI) scans. These 
common methods of detection each have their drawbacks. Biopsies are invasive and usually 
require the patient to undergo surgery, while CT scans use ionizing radiation, thus subjecting the 
patient to radiological health risks. Although MRI scans are generally less invasive, they 
introduce additional hassles for the patient. MRI relies on magnetic fields which can affect any 
magnetically susceptible metal. Metallic implants in patients, such as aneurysm clips, cardiac 
pacemakers, or insulin pumps may be damaged or shifted during an MRI scan. Additionally, 
these methods of detection are expensive and usually only capable of providing accurate 
detection and diagnostics information when the patient is in later stages of cancer. Whereas 
conventional cancer detection methods involve invasive procedures and is mostly conducted at 
the macroscopic tissue level, the proposed device seeks to detect cancer metastasis and progress 
at a cellular level in a minimally invasive way. 
Due to the drawbacks in conventional detection and diagnostic methods, much research 
has been dedicated to other methods. Development of devices embodying characteristics of 
point-of-care systems, including low cost, highly mobile, and miniaturization, has been favored 
and advantageous. The small amounts of reagents and samples required by these point-of-care 
devices have the potential to greatly reduce the cost of a single test, as well as promoting patient 
compliance. Miniaturization of the devices enables samples to be easily transferred from place to 
place when needed, increasing convenience and efficiency for both medical doctors and clinical 
patients.  
Recent developments in point-of-care detection systems have strongly emphasized and 
concentrated on the capture and detection of CTCs as early indications of cancer by means of 
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biomarker assessment. The presence of CTCs may also provide information about a patient’s 
current disease state [5]. However, devices developed for the purpose of capturing and detecting 
CTCs must be both sensitive as well as specific given the fact that CTCs are extremely rare. CTC 
counts can be as low as one CTC per 10
6
 – 107 leukocytes [4]. Additionally, the presence of 
several various types and subtypes of biomarkers on the surface of the CTC during different 
stages of the cellular growth makes it difficult for enumerating and detecting CTCs in a 
consistent manner [4, 6, 7]. Hence, several studies have been dedicated to finding specific 
biomarkers that are typically overexpressed and can effectively distinguish CTCs from other 
cells of the body. Some commonly known biomarkers include prostate-specific antigen (PSA) 
for detection of prostate cancer [6] and human epidermal growth factor receptor 2 (HER2) for 
breast cancer [8].  
A prime example of a developing early diagnostic point-of-care system that utilizes 
biomarker detection of CTCs is the CellSearch
®
 CTC Test from Veridex, LLC, a subsidiary 
company of Johnson & Johnson. CellSearch
®
 is designed as a blood test capable of helping 
doctors predict disease state and provide a relatively accurate prognosis for patients with 
metastatic breast, colorectal, or prostate cancer based on the number of CTCs found within a 
tube of blood [9]. The system captures and detects CTCs through the use of epithelial cell 
adhesion molecule (EpCAM) coated magnetic nanoparticles which bind to CTCs in the patient 
blood sample [10].  
Although the CellSearch
®
 CTC Test has been approved and cleared for marketing by 
FDA, and has made considerable advancement in cancer diagnostics and detection, it still has its 
limitations. For one, a system solely reliant on a single biomarker may be questionable in terms 
of its sensitivity due to the versatile nature of cellular biomarker expression depending on the 
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individual cell and the stage of growth [11, 12]. The system is also limited in terms of its 
capability for post cell analysis, assessment, and imaging. Since it is a liquid based test, cells 
remain suspended in blood sample during capture and immunofluorescence analysis, after which 
the sample is discarded, along with the CTCs.  
The detection system presented in this thesis aims to address the previously stated issues 
concerning capture and detection of CTCs, as well as introduce design aspects to enhance the 
capturing, imaging, and analysis process. The proposed system, shown in Figure 1, consists of 
three primary components: a microcontact printed nanoporous silica substrate for enhanced 
protein absorption and deposition, a microfluidic channel for closer interaction between 
antibodies and cells and high throughput capability, and quantum dots (QDs) for effective and 
stable imaging of cells with potential for simultaneous multicolor detection.  
 
 
Figure 1. Proposed CTC Detection System. The device consists of three major components: 1) a 
microcontact printed nanoporous silica substrate, 2) a microfluidic channel, and 3) quantum dots. 
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Ultimately, when integrated together, the three components will produce a low cost, high 
throughput, miniaturized point-of-care device designed for the capture, detection, imaging, and 
analysis of CTCs in patient blood samples.  
1.2 Thesis Organization 
 This thesis documents the development of microchips that combines the advantages of 
micro and nanotechnologies to create effective and efficient platforms for various biological 
applications. In particular, the microchips make use of 1) microcontact printing, 2) nanoporous 
silica substrates, 3) quantum dots, and 4) microfluidic channels. The feasibility of the 
combination of such technologies was demonstrated in the performance of high throughput 
enzyme linked immunosorbent assays for food allergen detection and multicolor micropatterning. 
Ultimately, the most important and the primary focus of the thesis is designing a microchip-
based platform that combines the advantages of the technologies for the purpose of effective and 
efficient capturing, imaging, and analysis of cancer cells.  
The first part of the thesis focuses on introducing the micro and nanotechnologies and 
techniques of particular interest and utilized in the final microchip platform. This part introduces 
the effectiveness of the combination of the microcontact printing (µCP) technique on a 
nanoporous silica substrate in protein detection for multicolor patterning and immunoassays. The 
concept behind the use of the µCP technique involves simple uniform monolayer deposition and 
transfer of proteins that also enables potential multiplexing of multiple antibodies on a single 
substrate for selective and specific multiple antigen detection. Incorporation of the nanoporous 
silica substrate involves enhanced protein and antibody absorption that allow for more effective 
and efficient detection. In addition, quantum dots will be introduced to emphasize the benefits of 
QD immunofluorescence labeling of cancer cells. The use of QDs for immunofluorescence 
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labeling of cancer cells involves the capability for brighter, more stable, and potentially 
simultaneous multicolor imaging. Finally, microchannels will be introduced to form the final 
microchip-based platform for cancer cell capture and detection. The concept behind the use of a 
microfluidic channel involves finding optimal microchannel dimensions and geometries, as well 
as optimal flow conditions, for enhanced antibody and cancer cell interaction and binding. 
The second part of the thesis focuses on demonstrating the application of the technologies 
described in the first half. In particular, demonstration of proof of concept of the static capturing 
of cancer cells and site-specific targeted cancer cell capture using a microchip platform that 
derives its working principles from the advantages of the µCP technique and nanoporous silica. 
This part also emphasizes the benefits of QD immunofluorescence labeling of cancer cells. To 
complete the platform, a study of the effects of integrating the previously mentioned components 
with a geometrically-defined grooved microfluidic channel, thus converting the system to a 
dynamic system by introducing flow is demonstrated. This last part illustrates the enhanced 
effect on the capture numbers of cancer cells in the dynamic microfluidic system with the 
capture numbers of cancer cells in the static system introduced earlier. 
 Finally, the thesis concludes with an introduction of future applications and prospects for 
the utilization of the cancer cell capturing microchip. In general, typical immunoassays require 
long procedures that involve the use of microliter well plates and generous amounts of reagents, 
and quantification using spectrophotometry. Miniaturization of such systems onto a single 
microchip, allows for a low cost and high throughput device, both key characteristics of point-of-
care devices. More interestingly, as shown in this thesis, the fundamental working principles of 
the microchips have potential to be applied across various biological applications.  
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2 Microcontact Printing on Nanoporous Silica Substrate 
 
This section of the thesis introduces the advantages of the µCP technique coupled with 
nanoporous silica substrates. These two micro and nanotechnologies are integrated to 
demonstrate its advantage in enhancing the detection of proteins of interest. These fundamental 
working principles can be expanded to provide an attractive system for various biological 
detection systems or biosensors as described later. 
2.1 Nanoporous Silica Thin Film Substrates 
Conventional methods of surface functionalization involve chemical modifications in 
order to either increase or decrease substrate affinity for particular proteins, depending on the 
specific application [13–16]. Chemical modifications of surfaces to increase protein affinity 
usually involve the use of silane compounds that have terminal functional groups that can 
interact electrostatically or covalently with protein surface groups. Although chemical 
modification has been shown to yield effective results in increasing protein absorption, the 
processes involved are normally intricate and detailed in nature. Physical surface modifications, 
such as creating porous thin film structures for deposition on a substrate surface, are relatively 
straightforward approaches to surface modification. Nanoporous thin film characteristics are also 
easy to manipulate by changing fabrication conditions.  
The physical structures of the porous thin film allow for size-selective trapping of 
proteins and thereby enhancing protein absorption [17–20]. It has been previously shown by 
Blinka et al., that nanoporous silica thin film functionalized substrates enhance protein adhesion 
and adsorption onto the substrate surface more so than surfaces functionalized by chemicals such 
as 3-aminopropyltriethoxysilane (APTES) and glutaraldehyde (GA). Additionally, upon 
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comparison of nanoporous silica substrates with varying pore sizes, thin film thicknesses, and 
porosities, it was shown that nanoporous silica substrates characterized by 4 nm pores, 30 – 100 
nm thin film thickness, and 57% porosity were most effective in protein absorption [17]. By 
using nanoporous silica thin film substrates for enhanced protein absorption, it can be ascertained 
that the microcontact printed capture antibody is effectively transferred and absorbed onto the 
microchip substrate surface. 
Here, a nanoporous silica thin film of about 100 nm in thickness, with 4 nm pores and a 
porosity of 57%, is deposited on silicon substrate to form the base of the detection system. The 
µCP technique, described later, is employed in the deposition and transfer of the capture 
antibody onto the nanoporous silica substrate surface. The resulting stamped samples are 
characterized to verify the formation of an antibody self-assembled monolayer (SAM) and 
uniformity of the stamped antibody layer. Because immunoglobin G (IgG) antibodies have 
typical dimensions of 8.5 nm x 14.4 nm x 4 nm [21] (see Figure 2), the 4 nm pores of the porous 
silica thin film assist in anchoring and securing antibodies in place on the substrate, aligning 
them so that the epitopes are optimally 
exposed to antigens for binding. Additionally, 
the porous nature of the thin film increases 
the surface area of substrate area which 
comes into contact with the µCP stamp, and 
thus increases the capture antibody density 
per unit area. The increase in antibody 
density enhances the sensitivity of the 
microchip, a critical aspect of detection 
 Figure 2. Typical IgG Antibody. A typical IgG 
antibody has the dimensions of 8.5 x 14.4 x 4 nm. 
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systems and ultimately, the goal of the proposed detection microchip presented in this thesis. 
2.1.1 Fabrication of Porous Silica Substrates 
 
The nanoporous silica thin film substrates were fabricated according to the conditions and 
methods described by Blinka et al. [17] for substrates with 4 nm pore sizes, 130 + 0.5 nm 
thickness, and 52.4 + 0.2% porosity. In summary, surfactant micelles were formed by self-
assembly between polymer units and mixed with soluble silicates, tetraethyl orthosilicate 
(TEOS) and tetraethoxysilane, in homogeneous, hydro-alcoholic solutions. As the solvent 
evaporates during spin coating, the increase in polymer concentration causes the solution to 
exceed critical micelle concentration, driving silica/copolymer self-assembly into a uniform thin-
film nanophase.  
TEOS was dissolved in a mixture of ethanol (EtOH), distilled water (diH2O), and 
hydrochloric acid (HCl) and stirred for 2 hr at 75 
o
C
 
to form a clear silicate solution. Pluronic 
F127, a triblock copolymer (PEO106–PPO70–PEO106), was dissolved in EtOH and stirred at room 
temperature.  The silicate solution was 
mixed into the F127-EtOH solution and 
stirred for 2 hr at room temperature. The 
resulting solution was deposited onto a 
silicon wafer by spin coating at a spin rate 
of 1500 rpm for 20 s, and then heated at 80 
o
C for 12 hr. The films were calcinated at 
425 
o
C for 5 hr. to remove the organic 
surfactant. The nanoporous silica substrate 
surface was then oxygen plasma treated with an oxygen flow rate of 80 sccm and a power of 300 
Figure 3. Nanoporous Silica Substrate 
Fabrication. Schematic of the fabrication process of 
thin film nanoporous silica substrates [21] . 
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W for 10 min. Figure 3 shows the schematic of the fabrication of the nanoporous silica 
substrates. 
The thickness of the thin film was controlled by adjusting the concentration of Pluronic 
F127. The porosity depends on the molar ratio of polymer and silicate in the starting material. 
2.2 Microcontact Printing 
Microcontact printing (µCP) was first introduced in 1993 by George M. Whitesides 
group as a method for producing self-assembled monolayers (SAMs) [22]. In contrast to 
conventional methods of creating SAMs, which involves an initial chemical modification of the 
substrate surface before molecules chemically bind to the surface, µCP involves simple physical 
contact between substrate and a stamp. Additionally, the technique provides greater convenience 
as well as flexibility due to its patterning capabilities. SAMs of various geometries and sizes 
ranging from micron to sub-micron features can be patterned [23]. Given its advantages over 
conventional methods of creating SAMs, µCP has been employed in a wide variety of 
applications, mostly in the fabrication of biosensors. It has been used in the patterning of proteins 
in immunoassays [17, 24–29], patterning of cells [29–32], and optical arrays [33–35]. µCP has 
provided an easy and simple method for quick surface functionalization with potential for 
multiplexing capabilities, a critical advantage when performing procedures such as 
immunoassays [15, 16].  
The ability to pattern multiple proteins for multiplexing capability on a single substrate 
on a miniaturized scale is important in creating efficient point-of-care detection and analysis 
systems, which is the ultimate goal of the devices presented in this thesis. 
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2.2.1 Multicolor Microcontact Printing 
 
Poly(dimethylsiloxane) (PDMS) stamps were fabricated from hard silicon masters [36] 
with 100 μm diameter by 20 μm high circular patterns and 
four corner alignment marks. The circular pattern on the two 
separate stamps of a set alternated so that when aligned 
correctly using the alignment marks, will form an alternating 
pattern (ABABAB).  Stamps with pattern A were inked with 
a 5 μg mL-1 FITC-tagged (fluorescein isothiocyanate) anti-
rabbit IgG (Sigma Aldrich) solution for 20 min. Stamps with 
pattern B were inked with a 5 μg mL-1 TRITC-tagged 
(tetramethyl rhodamine iso-thiocyanate) anti-rabbit IgG 
(Sigma Aldrich) solution for 20 min. Both stamps were 
washed with 0.01 M phosphate buffer saline solution (PBS) and de-ionized water (diH2O) and 
dried under nitrogen (N2) gas. Figure 4 shows the basic schematic for µCP of a single protein 
onto nanoporous silica substrate. Stamp A and B were sequentially brought into contact with the 
nanoporous silica substrate for 1 min. Printing was 
done manually using a home-built stamping 
apparatus with a stamp-carrying part capable of 
micrometer level translations in the x, y, and z 
directions, to allow alignment precision within 5 µm 
(see Figure 5). In order to align the stamps and 
create a patterned substrate of the two different 
proteins, alignment markings on both stamps were 
aligned with corresponding alignment markings on the substrate. To visualize the alignment of 
Figure 4. Microcontact Printing. 
Schematic of the microcontact 
printing process. 
Figure 5. Microcontact Printing Apparatus. 
Schematic of the µCP apparatus that allows for 
x, y, and z directional translations for precise 
alignment visualized using a microscope. 
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the stamp with the substrate, a microscope with 5X was positioned above the apparatus. Figure 6 
shows the schematic for multiple microcontact printing. Transferred protein layers were analyzed 
by fluorescence (Olympus BX51) and atomic force microscopy (AFM; Digital Instruments 
Series IV, Veeco) for surface thickness and roughness to show uniform monolayer deposition of 
proteins. 
 
 
 
 
 
 
Figure 6. Multicolor Multiple Microcontact Printing. Schematic of multiple microcontact 
printing. The alignment marks on the two stamps were aligned with corresponding alignment marks 
on the nanoporous silica substrate to ensure a patterning of the two different proteins. 
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2.2.2 Optical Observations of Multicolor Protein Patterning  
 
It was first demonstrated that two different proteins could be simultaneously 
microcontact printed onto a single substrate via careful manual alignment of a set of 
complementary stamps to the nanoporous silica substrate, facilitated by corresponding alignment 
markings on both stamps and substrate. The nanoporous silica substrate was put under a 
fluorescence microscope and excited under the FITC filter (excitation wavelength ~490 nm) and 
the TRITC filter (excitation wavelength ~557 nm). Both proteins fluoresced under their 
respective filters. Under the FITC filter, only the FITC rabbit IgG circular pattern showed 
positive green fluorescence, while TRITC rabbit IgG showed little to no fluorescence. Under the 
TRITC filter, only the TRITC rabbit IgG circular pattern showed positive red-orange 
fluorescence, while FITC rabbit IgG showed little to no fluorescence. This indicates successful 
transfer of the proteins and hence successful multicolor microcontact printing of two different 
proteins on the same substrate. Figure 7 shows the resulting fluorescence microscopy pictures. 
As shown in the overlay, the alignment of the two stamps on the substrate was relatively precise, 
giving a small amount of displacement (about 30 μm). Because the stamping was manually 
performed and relative precision was eyeballed, there is large room for human error. Although 
30 μm may seem small, on a nanoscale level, it is relatively large. Future improvements to the 
microcontact printing apparatus, perhaps even development of an automated apparatus, will 
potentially increase the precision and accuracy of alignment. However, such is beyond the scope 
of this thesis, and as shown by the overlay, a successful multicolor multicontact printing of two 
different proteins was demonstrated.  
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2.2.3 AFM Characterization of Printed Protein Layers 
 
The stamped protein layers were analyzed using AFM microscopy and Vernier LabPro to 
evaluate the consistency of the transfer of proteins from PDMS stamp to nanoporous silica 
substrate. Ten FITC protein circles and five TRITC protein circles were arbitrarily chosen on the 
substrate and evaluated for protein layer thickness and surface roughness. To calculate thickness 
data, AFM pictures were divided into regions of protein coverage and regions of background. 1 
μm2 areas were taken from the area where the regions bordered each other. For each area, the 
background height was subtracted from the protein layer height to get a thickness value. A 
similar method of calculate surface roughness was used. Figure 8 shows fluorescence and AFM 
images obtained from a single circle of both FITC and TRITC-labeled microcontact printed 
Figure 7. Multicolor Immunofluorescence Detection of Proteins. (Top, left to right): PDMS stamp used to 
stamp FITC rabbit IgG antibodies; PDMS stamped used to stamp TRITC rabbit IgG antibodies; nanoporous silica 
substrate. All three have corresponding alignment markings to facilitate accurate stamping. (Bottom, left to right): 
Fluorescence microscopy pictures of substrate viewed under FITC filter; substrate under TRITC filters; overlay of 
the two pictures. The proteins on the substrate fluoresced under respective filters and the overlay demonstrates 
preciseness of alignment and no overlapping. 
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proteins. Table 1 shows the resulting overall average thickness and roughness for the FITC and 
TRITC proteins. The average thickness of the FITC protein layer deposited onto the nanoporous 
substrate was 8.496 nm with a standard deviation of 1.064 nm. The average surface roughness 
was 0.301 nm. The average thickness 
of the deposited TRITC protein layer 
was 9.271 nm with a standard 
deviation of 1.075 nm. The average 
surface roughness was 0.656. The 
dimensions of IgG have been 
reported as 8.5 nm × 14.4 nm × 4 nm 
[21]. The height dimensions observed 
for the printed protein molecules are 
consistent with these accepted 
dimensions for rabbit IgG. This 
indicates that the microcontact 
printing method was, on average, able to consistently deposit a single monolayer of rabbit IgG 
antibodies onto the surface of the nanoporous silica substrate. Furthermore, the average surface 
roughness is relatively low (at most 0.66 nm), indicating the layer deposited onto the substrate is 
relatively uniform in coverage [17].  
Table 1. Thickness and roughness measurements of printed proteins. 
 
Proteins Number of Samples Thickness (nm) Roughness (nm) Standard Deviation (nm)
TRITC 5 8.496 0.301 1.064
FITC 10 9.271 0.656 1.075
Figure 8. Quantification of Printed Protein Layers. 
Fluorescence and AFM images of both FITC and TRITC labeled 
circular microcontact printed proteins. 
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2.3 Patterned Sandwich Enzyme Linked Immunosorbent Assay 
Enzyme linked immunosorbent assay (ELISA) is a technique used to detect the presence 
of specific proteins or antigens in a sample [37]. There are many different types of ELISAs. The 
direct ELISA is considered the simplest type of ELISA in which the antigen is directly adsorbed 
to a plastic plate and detected by an enzyme-antibody complex. Upon addition of the enzyme’s 
substrate, the enzyme will produce a signal, usually a color change, indicating the presence of the 
antigen. The indirect ELISA is similar to the direct ELISA. However, instead of a single 
detection antibody, an indirect ELISA uses two antibodies. A primary antibody is used to detect 
and bind to the antigen while a secondary enzyme-antibody complex is used to detect and bind to 
the primary antibody. Upon addition of the enzyme’s substrate, it is the secondary antibody that 
displays a signal. The sandwich ELISA fixes a capture antibody to the surface to which the 
antigen of interest binds to. Primary antibody is then used to detect the antigen, and secondary 
enzyme-antibody is used to detect the primary antibody [38]. Addition of the enzyme’s substrate 
produces a detectable signal. In fluorescence ELISA, when light of a specific wavelength is 
shone upon the sample, the antigen-antibody complex will fluoresce and the amount or 
concentration of antigen in the sample can be inferred by the magnitude or the intensity of the 
fluorescence signal.  
Typical ELISA testing requires long procedures involving the use of microliter well 
plates as well as generous amounts of reagents for each immunoassay performed, and quantified 
using spectrophotometry comparisons with standards [37, 39–41].  As proof of principle and 
demonstration of application, a sandwich ELISA for simultaneous detection of two common 
food allergens, ovomucoid found in egg white and casein found in milk, was performed. The 
ability to microcontact print and detect multiple antigens in a single sitting, coupled with 
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fluorescence optical detection and quantification, lays grounds for the potential of creating more 
efficient immunoassays and biosensors. The ability to also miniaturize and microscale the 
immunoassay itself enables wider, more cost efficient, varieties of biomedical point of care 
diagnostics. 
2.3.1 Protein Sample Extraction 
 
A white hen egg (Hill Country) was purchased from a local grocery store, cracked, and 
the egg yolk was separated from the egg white. The egg white was diluted in PBS to form a 25 
μg mL-1 solution. Skim milk (Oak Farm) was purchased from a local grocery store. The milk was 
heated to 40 
o
C and reacted with 2% vinegar (acetic acid) in a drop by drop technique to separate 
the two milk proteins, whey and casein. The whey was discarded and the casein was diluted in 
PBS to form a 25 μg mL-1 solution. Both egg white and milk solutions were then subjected to 
heated ultrasonification using an ultrasonic cleaner (Crest 275) to further break down the sample 
into a uniform solution. 
2.3.2 Microcontact Printed Sandwich ELISA 
 
Stamps with one pattern (A) of 100 μm circles were inked with a 5 μg mL-1 mouse anti-
chicken ovomucoid (Cosmo Bio) capture antibody solution for 20 min. Stamps with a second 
pattern (B) of 100 µm circles were inked with a 5 μg mL-1 mouse anti-casein kinase 1, γ1 (Sigma 
Aldrich) capture antibody solution for 20 min. Both stamps were washed with 0.01 M PBS 
solution and (diH2O) and dried under N2 gas. Alignment of the stamps with the substrate surfaces 
and printing was done manually using the home-built stamping apparatus facilitated by a 
microscope positioned above the apparatus. Stamps A and B were brought into contact with 
nanoporous silica substrates for 1 min. 
 18 | P a g e  
 
 To prevent non-specific binding, 20 μL of 5% bovine serum albumin (BSA) solution was 
pipetted onto the surface of the substrates over the protein stamped area in a blocking step. The 
samples were incubated overnight at 4 
o
C and then triple washed at 5 min intervals using 0.01 M 
PBS solution. 20 μL of the egg white sample solution was pipetted onto the surface of substrate 
A and 20 μL of the milk sample solution, onto the substrate B. Both samples were incubated for 
2 hours at room temperature and then washed in the same manner as previously. 20 μL of 5 μg 
mL
-1
 rabbit anti-chicken ovomucoid (Alpha Diagnostic International) primary antibody was 
pipetted onto the surface of substrate A and 20 μL of 5 μg mL-1 rabbit anti-casein kinase 1, α1 
(Sigma Aldrich) primary antibody, onto substrate B. Samples were incubated for 2 hours at room 
temperature and then subjected to a washing step. 20 μL of 5 μg mL-1 of FITC-tagged anti-rabbit 
IgG was pipetted onto the surface of substrate A and 20 μL of 5 μg mL-1 of TRITC-tagged anti-
rabbit IgG, onto substrate B. Samples were incubated for 1 hour at room temperature and then 
subjected to a final washing step. Figure 9 shows the schematic for microcontact printed 
sandwich ELISA process and the theoretical molecular structure of a single microcontact printed 
Figure 9. Micropatterned ELISA. (a) Theoretical molecular structure of a single sandwich ELISA. The 
ultimate binding of the detecting secondary antibody, tagged by a fluorophore, enables optical detection 
when excited by a light source. (b) Schematic of the microcontact sandwich ELISA process. The capture 
antibody is microcontact printed onto the nanoporous silica substrate surface. Subsequent pipetting of 
specific antibodies builds and completes the sandwich ELISA.  
(b) 
(a) 
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sandwich ELISA on the surface of a nanoporous silica substrate. Each substrate was viewed by 
fluorescence microscopy (Olympus BX51) for positive detection of component antigens.  
2.3.3 Results and Discussion 
 
The ability to incorporate the µCP technique to perform a sandwich ELISA on the 
surface of a nanoporous silica substrate was demonstrated. The detection of common allergens 
egg white protein ovomucoid and milk protein casein was performed. The two sample substrates 
were observed under a fluorescence microscope under FITC and TRITC filters. Both samples 
fluoresced under their respective filters indicating positive detection of the allergens and 
successful microcontact printed sandwich ELISAs. FITC-detected ovomucoid fluoresced green 
under the FITC filter while showing little to no fluorescence under the TRITC filter. TRITC-
detected casein fluoresced red-orange under the TRITC filter while showing little to no 
fluorescence under the FITC filter. The detection method was therefore successfully specific to 
the desired allergen under examination. Figure 10 shows the fluorescence microscopy pictures 
of both sample substrates.  
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2.4 Conclusion 
In this part of the thesis, a method for multicolor microcontact printing on nanoporous 
silica substrate that allows from more efficient detection of multiple proteins on a single 
substrate with a potential for enhancing diagnostic power of immunoassays was described. In 
addition, it was demonstrated that the method had the capability to perform a miniaturized 
sandwich ELISA to detect common food allergens, such as egg white ovomucoid and milk 
casein, on nanoporous silica substrate using the microcontact printing technique. The use of 
nanoporous silica membranes as substrate material allows versatile surface functionalization and 
provides for better protein adhesion and adsorption. The ability to microcontact print multiple 
proteins onto the same substrate surface allows for high-throughput manufacturing of compact 
systems with planar device structures, ideal for detection on-chip designs. Furthermore, such 
capability has great potential in increasing the efficiency of immunoassays, such as sandwich 
ELISAs, with the ability to detect two antigens simultaneously. With further extension of the 
multicolor microcontact printing method described here, a sandwich ELISA of two different 
Figure 10. Fluorescence Imaging of Micropatterned Sandwich ELISA. Fluorescence microscopy pictures of 
the microcontact printed sandwich ELISAs on nanoporous silica substrates. (a) FITC-tagged egg white 
ovomucoid and (b) TRITC-tagged milk casein. 
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antigens could be conducted on the same substrate. Food samples containing both egg white and 
milk would be able to be detected simultaneously on the same substrate. 
Most importantly, µCP on nanoporous silica can have large impact on the effectiveness 
and efficiency of capturing cancer cells for cancer cell detection in applications of cancer 
diagnostics and detection. Such an application will be demonstrated in later sections. 
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3 Quantum Dots as Contrast Agents 
 
Conventional fluorescence labeling and markers have typically been organic dyes, such 
as fluorescein isothiocyanate (FITC) and tetramethyl rhodamine isothiocyanate (TRITC), and 
many researchers have long been seeking answers to their many limitations. Organic dyes are not 
photostable and photobleach under light exposure or long term storage. They also exhibit only 
single excitation and single emission wavelengths. In recent years, quantum dots (QDs) have 
been growing and receiving much attention in addressing the limitations presented by organic 
dyes.  
QDs are nanoparticles, or more specifically nanocrystals, with tunable emission 
wavelengths and are composed of semiconductor material, usually cadmium or zinc. Because 
QDs are semiconductors, they have electrical conductivity between that of a conductor and an 
insulator. Metals are highly conductive due to a large density of available states in which 
electrons can occupy in the Fermi level, the highest occupied molecular orbital in the valance 
band or the energy below which there is a 50% chance of finding an occupied energy state. 
Electrons can therefore move freely between energy levels. Insulators on the other hand, have 
large energy band gaps between the electron-occupied energy levels and empty energy levels, 
limiting electron motion. Semiconductors therefore have an intermediate level of electric 
conductivity. They have a band gap small enough for sufficient numbers of electrons to jump 
from the lower energy valance band to the conduction band. This movement of electrons creates 
electron holes in the valance band and the presence of loosely held electrons in the conduction 
band. Furthermore, electrons may move around to fill a hole contributing to electrical 
conductivity [42].  
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The size of the QDs determines the wavelength it emits allowing for tunable emission 
wavelengths (shown in Figure 11), making them attractive for multicolor detection systems. 
This unique characteristic of QDs can be attributed to quantum confinement. In the 
semiconductor crystal lattice, electrons are squeezed together, a phenomena explained by the 
Pauli exclusion principle, which states that no two electrons can simultaneously occupy the same 
quantum state. The number of energy levels are therefore determined and restricted by the size of 
the QD. Smaller QDs have a larger band gap and therefore a greater difference in energy 
between the highest valence band and the lowest conduction band. More energy is needed to 
excite the QD which in turn, results in larger amounts of energy released when the QD returns to 
resting state. In contrast, larger QDs have a smaller band gap and less energy is needed to excite 
the QD, resulting in less energy released when the QD returns to resting state. Because of this 
size-tunable advantage, high levels of synthesis control over fabrication can be used to 
implement precise control over the conductive properties of the material [42–45].  
 
Another key advantage QDs have, is their capability to be excited by a single excitation 
light source. They have a broad absorption range and single emission wavelength, allowing for 
simultaneous excitation and viewing of multiple fluorescence markers with a single excitation 
Figure 11. Synthesized Colloidal QDs. QDs made of CdSe:ZnS. QDs exhibit broad excitation range and narrow 
single wavelength emission allowing them to be excited with a single light source. This unique multicolor property 
of QDs is due to their size-tunable advantage [46]. 
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light source. This advantage is attributed to the quantum confinement and size-dependent 
characteristic of QDs. High energy excitation light sources with shorter wavelengths, such as UV 
light sources, can easily excite QDs of any size resulting in an emission of lower energy and 
longer wavelengths in the visible light range of the electromagnetic spectrum. Due to quantum 
confinement, the energy and wavelength emitted is defined by the size of the QD and can be 
described as the sum of the band gap energy between occupied levels and unoccupied energy 
levels. This advantage provides the ability for multicolor immunofluorescence assays capable of 
distinguishing between different cancer cell lines. Additionally, QDs are brighter due to higher 
quantum yield and are more photostable than organic dyes thus enabling them to be exposed to 
light during long term storage without photobleaching. This advantage makes the microchip-
based cancer cell detection system capable of post screening analysis and imaging [42, 46, 47]. 
The recognition of the many advantages of QDs has led to an explosion of biological 
applications of QDs. One of the most rapidly growing applications is the use of QDs as imaging 
agents in in vitro imaging and detection of various cancer cell types (shown in Figure 12), such 
as prostate, breast, and pancreatic 
cancer [46, 48–51]. Detection and 
imaging for living cells in culture 
involve a simple detection via 
cancer cell biomarker specific 
labeled antibodies that are 
conjugated with QDs. However, 
unlike the monolayers of cultured 
cells and thin tissue sections, challenges arise with increase in complexity to multicellular 
Figure 12. Detection of HER2 with QD-IgG. Breast cancer SkBr3 
cells were incubated with monoclonal anti-HER2 antibody and 
fluorescently labeled with QD-labeled goat anti-mouse IgG. The cell 
on the left was labeled with QD535 IgG while the cell on the right 
was labeled with QD630 IgG [49]. 
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organisms where tissue thickness becomes a major concern. Biological tissue attenuates imaging 
signals. QDs have allowed for the fluorescence imaging of various biological tissues, such as 
blood vessels and lymph nodes [51]. 
 Another application QDs have been prominently used in is fluorescence resonance 
energy transfer (FRET) which involves the transfer of fluorescence energy from donor particle to 
an acceptor particle when the distance between the two is smaller than a critical radius, or the 
Foerster redius. QDs in FRET technologies can be used in immunoassays when they are 
conjugated to biological molecules, such as antibodies. QDs act as donors in assays. An example 
of bioconjugated QDs as biosensors is in quantitative maltose sensing where QDs are conjugated 
to maltose binding protein (MBP) and bind to either maltose or a quenching molecule which has 
a binding affinity similar to that of maltose. Upon addition of maltose, the quenching molecule is 
displaced and a concentration dependent increase in luminescence is observed. As demonstrated 
by this particular application, QDs make for a very reliable, stable, and bright detection and 
imaging system.  
The unique advantage of QDs’ characteristic broad excitation range and narrow single 
emission has garnered much attention in developing multicolor imaging systems. One such 
imaging system is hyperspectral microscopic imaging (HMI). HMI utilizes the various 
wavelengths across the electromagnetic spectrum to provide detailed images with more 
information than those provided by conventional microscopic imaging. Therefore, HMI with 
multiple fluorophore labeling is an effective tool for distinguishing between various cancer cell 
types. HMI has been employed to simultaneously image ten different tumor markers of a cell, as 
shown in Figure 13. Ultimately, by integrating QD-labeled cancer cells with the HMI process, 
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brighter and stabler photoluminescence can be achieved while simultaneously identifying various 
biomarkers in cells, enhancing specificity of detection and identification [52]. 
  
QDs have also been used in combination with various other nanotechnologies to create 
light source platforms that can potentially form the foundation for illumination of biological 
samples.  QDs have been used in conjunction with the µCP technique in electronics and 
optoelectronics such as light-emitting diodes (LEDs) and solar cells [33, 53, 54]. Gopal et al. has 
previously demonstrated localized electroluminescence for multicolor illumination of cancer 
cells on a single chip (see Figure 14) [55]. Stained cancer cell samples on a cover slip were 
placed over a multicolor QD-LED source and observed under a microscope while imaging the 
cells at different excitation wavelengths. Because different parts of cells fluoresce when excited 
by specific wavelengths, the platform was capable of imaging various parts of the cells under 
different excitation wavelengths. This application of QDs shows the utilization of QDs and its 
advantages to create an effective biological microchip-based imaging platform. In addition, it 
demonstrates the strength of combining various nanotechnologies into a single microchip 
platform that utilizes the advantages of each nanotechnology for effective biological applications. 
Similarly, the platform described in this thesis emphasizes the combination of various 
nanotechnologies and their advantages in a microchip based platform for biological applications, 
specifically, in cancer cell detection. 
 
Figure 13. HMI Cancer Cell Imaging. Quantification of ten fluorescent markers by HMI [38]. 
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In the work presented in this thesis, QDs are primarily used for the photostable and bright 
imaging of captured cancer cells on a micropatterned nanoporous silica substrate. QD imaging is 
an added advantage to the microchip-based platform, potentially extending the lifetime and shelf 
life of the chip post-screening and providing medical analyzers with an easy-to-spot and bright 
fluorescence signal for the detection of rare CTC cells in blood samples.  
  
Figure 14. Integrated Bioimaging System. Schematic of the integrated QD-LED microchip-based platform for 
the QD fluorescence imaging of cancer cells [55]. 
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4 Fundamentals of Microfluidic Channels 
Recent years have shown growing interest in microfluidic channels as biomedical devices 
in the clinical and point-of-care settings due to the advantages the channels incur on a microscale 
level. Microfluidics decrease the volume of reagents and samples needed to run an experiment, 
usually down to the micro or even nanoliter scale, making it extremely cost-effective. 
Microfluidic channels are also easy to design, fabricate, and mass produce using 
microfabrication and lithographic techniques. Multiple channels can be further used to achieve 
high throughput capabilities, reducing the amount of time needed to perform experiments and 
data analyses. The advantages of integrated microfluidic microchips allow for various functions 
to be performed on a micro or nanoscale level, especially for biologics and medical applications. 
Microchannels geometrically confine fluids to a sub-millimeter scale allowing for precise control 
and manipulation of fluids. Microfluidics have been used for DNA amplification and analysis 
[56–58], flow cytometry [59–61], immunoassays [15, 42–44], and point-of-care diagnostics [65]. 
Behavior of fluids at the microscale level can differ greatly from that at the macroscale 
level. Factors such as surface tension, energy dissipation, and fluidic resistance begin to 
dominate the system. Fluid flow relative to the static walls within a straight microfluidic channel 
can be characterized by the Reynolds number (Re) given by: 
   
   
 
 — (1) 
where ρ = density of the fluid, v = mean velocity of the object relative to the fluid, L = 
characteristic linear dimension, µ = dynamic viscosity of the fluid. The Re is a ratio between the 
inertial forces to viscous forces on the fluid. Flow in a microfluidic channel can be described as 
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laminar flow, where the Re is less than 2300, and the streamlines are steady and parallel to the 
direction of fluid movement (shown in Figure 16) [66, 67].  
 Microfluidic channels of various geometries can be 
fabricated and realized through simple microfabrication 
techniques. In addition, the ability to mass produce 
microchannels in a relatively straightforward and simple 
method reduces the cost of fabrication. Most of the 
microfluidic channels used in biological applications are 
made from polydimethylsiloxane (PDMS) molding which 
is a negative imprint of a silicon master. With current 
photolithographic technologies, creating the silicon master 
on a silicon wafer is relatively easy and time 
efficient. Briefly, patterns are designed on a 
computer-aided design (CAD) program and 
printed onto a mask. A silicon wafer is spin 
coated with photoresist, usually SU-8, to the 
thickness of the desired channel height. The mask 
is placed on top of the photoresist and exposed to 
UV light. The photoresist is then further 
developed in developing chemical to reveal a 
patterned silicon wafer. Once the master is 
created, simple polymerization of PDMS in the 
mold will yield the desired microchannel (see 
Figure 16. Flow Profiles within a 
Tube. Turbulent flow, shown in the top 
figure, exhibits a fluid with chaotic flow 
and no distinct streamlines. In contrast, 
laminar flow, shown in the bottom 
figure, exhibits a fluid with distinct 
streamlines that are parallel to the 
direction of fluid movement. 
Microfluidic channels are characterized 
by laminar flow [66]. 
Figure 15. Silicon Lithographic Fabrication of 
Microfluidic Channels. Schematic of the 
fabrication of silicon masters for microfluidic 
channels via soft lithographic methods. After the 
master is fabricated, PDMS polymer can be 
poured into the master to create the 
microchannel [68]. 
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Figure 15) [68]. Such easy fabrication methods has allowed microfluidic channels to be 
designed and fabricated rapidly and inexpensively, making them attractive for use in various 
biological applications and components for integrated systems. 
 The advantages that microchannels embody have been utilized in many biological 
applications. One of the more predominate applications is the capturing and detection of CTCs. 
One example of a microfluidic-based CTC screening system has been demonstrated by Hoshino 
et al. (see Figure 17) [69]. The microchip CTC screening system utilizes the advantages of the 
localized confinement defined by a microfluidic channel to perform immunomagnetic detection 
of CTCs. Microfluidics aided in the design and development of a low cost, highly specific and 
sensitive miniaturized screening platform by reducing reagent and sample volume and exposing 
nanoparticle-labeled cancer cells to a more localized magnetic field.  
 Integration of microfluidic channels with microcontact printed nanoporous silica based 
microchips can enhance the capture of cancer cells. The microchannel can be designed to 
increase the binding 
interactions between 
microcontact printed 
antibodies on the 
nanoporous silica substrate 
and cellular biomarker 
antigens present on the cell 
surface. Furthermore, the 
laminar flow that 
characterizes microfluidic channels can be disrupted, and turbulent flow can be introduced 
Figure 17. Microchip-based Immunomagnetic Detection of Cancer 
Cells. Schematic of the immunomagnetic detection of cancer cells. The 
microfluidic channel aids in bringing nanoparticle-labeled cancer cells 
closer to the magnets below the cover slip. In addition, the confinement of 
reagents and samples to a small volume reduces cost effectively [69]. 
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through the utilization of grooved microchannels. Grooved microchannels create a micromixed 
environment within the channel and therefore brings cells even closer to the surface, increasing 
the probability for cell-surface interactions [70–72]. 
 Grooved microchannels have been examined as a method to introduce turbulent flow into 
the otherwise laminar environment that characterizes the flow within a straight microchannel. 
One of the more prominently looked at methods and designs for such channels are the 
micropillars and herringbone structures first introduced by Nagrath et al. and  Stott et al., in the 
CTC-Chip [70] and the HB-Chip [73], respectively (see Figure 18). In both cases, the 
micropillars and the herringbone structures introduced a micromixing environment within the 
channel that brought the cells closer to the surface of the microchip, allowing for enhanced 
interactions between the capture antibodies coated on the micropillars or within the microchannel 
and the biomarkers on the surface of the cancer cell. In addition, optimal surface interaction 
geometry was characterized for the herringbone structure microchannels. It was found that 
groove widths of about 125 µm were optimal for cell-surface interactions. 
Figure 18. CTC-Chip and HB-Chip. The CTC-Chip and HB-Chip introduces physical obstacles within the 
microfluidic channel in order to create a micromixing environment within the channel. The CTC-Chip (a) 
uses EpCAM-functionalized micropillars and the HB-Chip (b) uses EpCAM coated microchannel with 
herringbone structures [73]. 
(a) (b) 
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 Aside from cancer cell detection, microfluidic channels have been used in other 
applications, such as biosensors, drug delivery systems, and biomimetic systems [74–76].  
Biomimetic systems in microfluidic channels have helped provide a miniaturized system on a 
microchip platform for various biological studies. Huh et al. developed the lung-on-a-chip, a 
flexible biomimetic chip designed to mimic the mechanical and biochemical behaviors of the 
human lung [74]. Through use of microfluidics, Huh was able to reconstitute the functional 
alveolar-capillary interface of the lung (see Figure 19). The culturing of cells into tissue or even 
whole organ systems provides a large advantage to understanding the basic fundamental biology 
of certain diseases. Such systems provide useful and effective platforms for drug studies and the 
cellular interactions that result in detrimental human diseases. Wu et al. developed a microfluidic 
platform designed to culture self-assembled tumor spheroids [76]. The platform allows for 
Figure 19. Lung-on-Chip. (A) The biomimetic microchip uses compartmentalized PDMS microchannels to form an 
alveolar-capillary barrier on a flexible PDMS membrane coated with ECM. (B) During inhalation in the lung, 
contraction of the diaphragm causes a pressure change that stretches the alveolar-capillary interface. (C) Three 
PDMS layers are aligned and bonded to form two sets of three parallel microchannels separated by a porous PDMS 
membrane. (D) PDMS etching is flowed through the side channels that leads to selective etching of the membrane 
layers to produce two large side chambers to which vacuum is applied to cause mechanical stretching. (E) Top view 
images of the actual lung-on-a-chip microfluidic device [74]. 
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further studies on the interactions of cancer cells on a cellular level and observation of the 
formation of tumors. In addition, it provides a platform for anticancer drug discovery.  
 In this thesis, microfluidic channels are used in enhancing cancer cell detection. A design 
example is presented in this thesis, consisting of a microchannel 20 mm long and 200 µm high, 
constructed with two grooves, each 5 mm wide, 100 µm deep, and spaced 3 mm apart from each 
other. The grooved microchannel presented in this thesis illustrates the ability to modify the 
channel geometries to enhance cell capture and cell-surface interactions by introducing 
micromixed environments within the channel. Additionally, site-specific capturing of cancer 
cells can be performed in accordance to channel geometries via simulations and modeling to 
determine optimal locations for cell capture within the microchannel. 
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5 Patterned ELISA Cancer Cell Detection 
This section of the thesis describes an application of three of the four technologies 
described and introduced in the first half of the thesis to perform immunofluorescence detection 
of QD labeled cancer cells. Here, the µCP technique is employed in the patterning of capture 
antibodies on nanoporous silica substrates, specifically anti-epithelial cell adhesion molecule 
(anti-EpCAM), in the capturing of breast cancer cells from cell line SkBr3 and colon cancer cells 
from cell line Colo205. As previously mentioned, SkBr3 and Colo205 cells have been known to 
overexpress EpCAM biomarkers on the cells’ surface [8]. In addition, SkBr3 cells have been 
known to overexpress anti-human epidermal growth factor receptor 2 (anti-HER2), while 
Colo205 cells display cytokeratin (CK) proteins. The method of detection is similar to that of a 
direct enzyme-linked immunoabsorbent assay (ELISA), where the capture antibody is 
microcontact printed on the substrate surface and subsequently used to capture SkBr3 and 
Colo205 cells onto the substrate, followed by fluorescence detection. Here, fluorescence 
detection and imaging of SkBr3 and Colo205 cells was performed using quantum dot (QD) 
labeled anti-HER2 and FITC labeled anti-CK detecting antibodies, respectively.  
5.1 Experimental Methods 
5.1.1 Cell Culture 
 
SkBr3 and MDA-MB-435 breast cancer cells were cultured in RPMI 1640 media, 
supplemented with 20% fetal bovine serum (FBS) (Gibco
®
, Invitrogen), and incubated in a 
humidified incubator (37 
o
C, 5% CO2). The cells were passaged biweekly or when needed, as 
follows. Old media was aspirated from the culturing plate and 5 mL phosphate buffer saline 
(PBS) was pipetted into the plate to rinse the cell layer. The PBS was aspirated and 3 mL of 
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trypsin (Gibco
®,
 Invitrogen) was pipetted into the plate and incubated for 10 min. After 
incubation for 10 min, 3 mL of media was pipetted into the plate to neutralize the trypsin and 
stop trypsinization. The cell suspension was pipetted into a conical centrifuge tube and 
centrifuged at 1000 rpm for 3 min. The supernatant was aspirated, leaving behind the cell pellet 
which was then resuspended in 1 mL media. A fraction of the cells were then pipetted into a new 
cell culture petri dish with 10 mL fresh media. Colo205 colon cancer cells were cultured in the 
same manner without trypsinization. Colo205 cells were centrifuged, resuspended in media, and 
split into a petri dish of fresh media. When needed for experimentation, cells were resuspended 
in PBS. Cell counts were performed using a hemocytometer (Hausser Scientific). A volume 
containing the desired number of cells was extracted from the cell suspension and resuspended in 
3 mL PBS in a new centrifuge tube. 
5.1.2 Microcontact Printing of Capture Antibody 
 
Polydimethylsiloxane (PDMS) stamps were fabricated using a mixture of 10:1 Sylgard 
184 silicone elastomer to curing agent (Dow Corning). The mixture was vigorously mixed and 
then placed in a desiccator to remove extraneous bubbles. The resulting mixture was carefully 
poured into a petri dish and extra bubbles were removed by blowing. The PDMS mixture was 
allowed to cure overnight at room temperature. When needed, the cured polymer was peeled 
from the silicon mold and cut into stamps with 5 mm x 5 mm square area.  
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Stamps were inked with the capture antibody, a 30 µg/mL anti-EpCAM solution, for 20 
min then washed with PBS and diH2O, and dried under N2 gas. Figure 20 shows the basic 
schematic for µCP proteins 
onto a nanoporous silica 
substrate. The stamps were 
brought into contact with the 
nanoproous silica substrate 
for 1 min. Printing was done 
manually using a home built 
mechanical apparatus. The 
apparatus consists of a 
stamp-carrying magnetic 
piece capable of micrometer 
translations in the x, y, and z 
directions allowing 
alignment precision within 5 
µm. To visualize the 
alignment of the stamp with the substrate and the actual contact between stamp and substrate, a 
microscope was positioned above the apparatus.  
Transferred antibody layers were characterized using atomic force microscopy (AFM; 
Digital Instruments Series IV, Veeco) for surface thickness and roughness to show uniform 
monolayer deposition of proteins. 
 
Figure 20. Microcontact printing process. (a) PDMS stamps are first 
inked with desired antibody solution and then stamped onto the porous 
silica substrate through direct physical contact. (b) A design of 10 mm x 
10 mm nanoporous silica substrate with anti-EpCAM patterned 5 mm x 5 
mm square areas. 
(a) 
(b) 
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5.1.3 Immunofluorescence Detection of QD Labeled Cancer Cells 
 
 
Here, QDs with an emission wavelength of 625 nm (QD625) were purchased as a part of 
a conjugation kit (Invitrogen). They were conjugated with anti-human epidermal growth factor 
receptor 2 (HER2) antibodies (Sigma Aldrich) via the conjugation method provided along with 
the kit. 10 µL of the QD625-labeled anti-HER2 (50 µg/mL) was pipetted into the previously 
prepared SkBr3 cell suspension 
(20,000 cells). The cell suspension 
was then placed into an incubation 
oven for 2 hour at 37 
o
C. Fluorescein 
isothiocyanate (FITC) labeled anti-
cytokeratin (CK, 20 µg/mL) (Sigma 
Aldrich) was pipetted into the 
previously prepared Colo205 cell 
suspension (20,000 cells). The cell 
suspension was then placed into an 
incubation oven for 1 hour at 37 
o
C. 
MDA-MB-435 cells were left 
unlabeled. 
To prevent non-specific 
binding, the surfaces of the anti-
EpCAM stamped nanoporous silica 
substrates were blocked using a 1% 
bovine serum albumin (BSA) 
Figure 21. Immunofluorescence Detection of QD-Labeled 
Cancer Cells. Microcontact printing process of antibodies (anti-
EpCAM) on nanoporous silica substrate for immunofluorescence 
detection of labeled (QD625 or FITC) cancer cells (SkBr3 or 
Colo205). 
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solution at 37 
o
C for 30 min. After blocking, the substrates were triple rinsed with PBS for 5 min 
intervals. The substrates were then placed into the three separate prepared cell suspensions 
(QD625-labeled SkBr3, FITC-labeled Colo205, and non-labeled MDA-MB-435) and placed on a 
vortex machine in a styrofoam conical centrifuge tube holder. The conical tubes were allowed to 
shake on the vortex machine at the lowest setting (Shake 1) for 3 hour at room temperature. The 
shaking motion that the vortex machine provides creates a slightly dynamic environment for the 
cells to have higher probability of interaction with the nanoporous silica substrate, and also 
serves to prevent cells from sinking to the bottom of the tube where they could remain sedentary. 
After 3 hour, the substrates were removed from the conical tube and gently placed into PBS for 5 
min to rinse off remaining free loose cells. Extraneous liquid was removed using Kimwipes. The 
substrates were placed into the freezer and allowed to freeze for 10 min at 4 
o
C. Captured cells 
on the nanoporous silica substrate were fixed with glacial acetone in the freezer at 4 
o
C for 10 
min. The nuclei of the cells were stained with DAPI. Each substrate was viewed by fluorescence 
microscopy (Olympus IX2-UCB). The number of cells in each test area was counted in a top to 
bottom fashion while incrementally moving in the translational direction. Figure 21 shows a 
schematic of the whole process of µCP of antibodies on nanoporous silica thin film substrate for 
immunofluorescence detection of labeled cancer cells. 
5.1.4 Statistical Analysis 
 
Statistical analysis was performed for the comparison of cell capture numbers between 
different conditions for a total of five experiments each performed under the same conditions 
(Section 5.1.3). The averages and standard deviations were tabulated for each experiment’s data 
set and the ANOVA test was used to make comparisons. Assumptions used when performing the 
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ANOVA test includes normality and equal variance. The ANOVA test uses the F statistic which 
can be calculated using the following equation: 
  
                
               
 — (2) 
where                 = the mean squares between groups and                = the mean 
squares within groups.                 can be calculated using the following equation: 
                 
∑( ̅   ̅)
 
   
 — (3) 
where  ̅= mean for all the data,   ̅= mean of group i, and I = number of groups.                
can be calculated using the following equation: 
                
∑(     ̅ )
 
   
 — (4) 
where    = value of measurement j in group i,   ̅= mean of group i, n = total number of 
measurements, and I = number of groups. The value of the F statistic can then be compared to 
the F(I – 1, n – I) distribution and a p-value is obtained. A p-value of less than 0.05 indicates that 
the means within the groups are statistically different and the null hypothesis is rejected. A p-
value greater than 0.05, indicates that the means within the groups are not statistically different 
and the null hypothesis is accepted. However, only performing the ANOVA test did not indicate 
which pairs were different; therefore a method that accounts for multiple data sets, such as the 
Tukey’s Method (a post hoc test), was used. 
 For the different experimental conditions, the data obtained were compared using the 
ANOVA test for differences. All ANOVA tests were performed using the MATLAB function 
anova1. A comparison between multiple data sets was then performed using the MATLAB 
multcompare function to determine which pairs were different. 
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5.2 Results and Discussion 
5.2.1 Characterization of Printed Capture Antibody 
 
The stamped anti-EpCAM layers were analyzed using AFM microscopy and NanoScope 
Analysis to determine the consistency of the transfer of the antibody from PDMS stamp to the 
nanoporous silica substrate. Five stamped areas were arbitrarily chosen on the substrate and 
evaluated for antibody layer thickness and surface roughness. Thickness data were calculated by 
dividing AFM images into regions 
of antibody coverage and regions of 
nanoporous silica substrate 
background. The background height 
was then subtracted from the protein 
layer height to obtain a thickness 
value. A similar method of 
calculating surface roughness was 
used within a 1 µm x 1 µm square 
area. Figure 22 shows an AFM 
image obtained from an area of 
microcontact printed anti-EpCAM 
along with the cross section plot of the sample. The average thickness of the antibody layer 
deposited onto the nanoporous silica substrate was 6.07 + 1.70 nm. The thickness dimensions are 
relatively consistent with the antibody dimensions previously reported [21]. This indicates that 
the microcontact printing method was able to deposit a monolayer of anti-EpCAM antibodies 
onto the surface of the nanoporous silica substrate. The average surface roughness was 0.54 + 
(a) 
Figure 22. Characterization of Patterned Nanoporous 
Substrates. AFM characterizations of microcontact printed anti-
EpCAM on nanoporous silica substrate: (a) thickness and 
roughness of antibody layer and (b) the cross section plot of the 
sample. 
(b) 
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0.32 nm. This low average surface roughness indicates that the antibody layer deposited is 
relatively uniform in coverage. 
5.2.2 Immunofluorescence Detection of QD Labeled Cancer Cells 
 
SkBr3 breast cancer cells were labeled with QD625-labeled anti-HER2, while Colo205 
colon cancer cells were labeled with FITC-labeled anti-CK. The SkBr3 and Colo205 cells were 
captured via antibody-antigen interactions between the cell surface and the stamped nanoporous 
silica substrate surface. Non-labeled MDA-MB-435 cells were used as a negative control. Non-
stamped areas of the substrate also served as a negative control. Fluorescence images were 
observed to verify and distinguish the presence of the various cells. SkBr3 cells are EpCAM 
positive and HER2 positive cells, and should therefore be captured on the substrate, labeled with 
QD625-labeled anti-HER2, and positive in DAPI. Colo205 cells are EpCAM positive and CK 
positive cells, and should therefore be captured on the substrate, labeled with FITC-labeled anti-
CK, and positive in DAPI. 
Figure 23a shows the identification of captured SkBr3 cells under the DAPI filter, under 
a filter cube (excitation peak wavelength 577 nm, bandwidth 20 nm; dichroic mirror 595 nm 
long-pass; emission peak wavelength 630 nm, bandwidth 30 nm) and as an overlay of the two 
previous images under 20X magnification. Figure 23b also shows the identification of a 
captured Colo205 cell under the DAPI filter, under the FITC filter, and as an overlay of the two 
previous images under 20X magnification. DAPI images were taken at an exposure time of 5 ms, 
QD625 images at an exposure time of 3 s, and FITC images at an exposure time of 150 ms. The 
nucleus of the cells, stained with DAPI fluoresced blue while the HER2 receptors on the surface 
of SkBr3 cells fluoresced red and the CK proteins of the Colo205 cytoskeleton fluoresced green. 
Figure 23c also contrasts the captured cell density within a defined area of no stamped anti-
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EpCAM antibodies with the captured cell density within an area with stamped anti-EpCAM on 
the nanoporous silica substrate. It can be seen that the captured cell density within the area of no 
stamped anti-EpCAM is lower than that within the area with stamped anti-EpCAM.  
 
Figure 23. Cancer Cell Imaging. Fluorescence microscopy images of captured SkBr3 cells and Colo205 cells on 
the nanoporous silica substrate. (a) The first row (left to right) images the SkBr3 cells’ QD625-labeled HER2 
surface receptors under a  filter cube, DAPI stained nuclei under the DAPI filter, and an overlay of the DAPI and 
QD625 images. (b) The second row (left to right) images the Colo205 cell’s FITC-labeled CK protein of the 
cytoskeleton under the FITC filter, DAPI stained nuclei under the DAPI filter, and an overlay of the DAPI and 
FITC images. (c) The third row (left to right) images the captured cell density within a defined area with no 
stamped anti-EpCAM, and the captured cell density within a defined area with stamped anti-EpCAM on the same 
nanoporous silica substrate. 
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5.2.3 Statistical Analysis: Cancer Cell Capture Numbers 
 
The number of captured cells for each experimental condition was counted within the 
defined 10 mm x 10 mm nanoporous silica square area for a total of five trials conducted under 
identical conditions. The average number of captured cells and respective standard deviations 
were obtained and the results are shown in Table 2. 
Table 2. Average captured cell numbers within the defined 1 cm x 1 cm nanoporous silica square area and 
respective standard deviations obtained from each of the six different experimental conditions. 
Cell Type Condition 
Stamped/No EpCAM 
Area 
Average Capture Number 
per 25 mm
2
 Area 
Standard 
Deviation 
SkBr3 
1 Stamped EpCAM 55.50 23.18 
2 No EpCAM 13.10 9.79 
Colo205 
3 Stamped EpCAM 29.10 10.38 
4 No EpCAM 5.10 3.67 
MDA-MB-435 
5 Stamped EpCAM 2.00 1.63 
6 No EpCAM 3.25 2.87 
  
Statistical analysis was performed to verify and compare the cancer cell capture numbers 
between the six different experimental conditions: 1) breast cancer cell line SkBr3 captured on 
microcontact printed anti-EpCAM nanoporous silica substrate, 2) SkBr3 captured on non-
functionalized nanoporous silica substrate (negative control), 3) colon cancer cell line Colo205 
captured on microcontact printed anti-EpCAM nanoporous silica substrate, 4) Colo205 captured 
on non-functionalized nanoporous silica substrate (negative control), 5) breast cancer cell line 
MDA-MB-435 captured on microcontact printed anti-EpCAM nanoporous silica substrate 
(negative control), and 6) MDA-MB-435 captured on non-functionalized nanoporous silica 
substrate (negative control). The one-way ANOVA test was used to calculate the F statistic, 
which in turn was used to determine the p-value. The p-value gives a measurement of how 
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statistically different the means of each experimental group are from each other. Here, a p-value 
of 0.05 is defined as the significance level. P-values greater than the significance level indicate 
that the means between experimental groups is not significantly different from each other. The 
opposite is true if p-values are equal to or less than the significance level. Further analysis using 
the Tukey’s Method verified which specific two groups were statistically different from each 
other. 
Table 3 shows the p-value for all group-by-group comparisons. Those outlined in green 
(*) (stamped EpCAM vs. non-stamped) and red (†) (experimental vs. control) indicate the major 
significant differences of importance that support the feasibility of the cell capture method. The 
one cell outlined in blue (‡) justifies the use of MDA-MB-435 cells as the negative control cell 
line. 
Table 3. Comparisons of all group-by-group p-values. 
  
SkBr3 Colo205 MDA-MB-435 
No 
EpCAM 
Stamped 
EpCAM 
No 
EpCAM 
Stamped 
EpCAM 
No 
EpCAM 
SkBr3 
Stamped EpCAM 4.589E-05
* 
4.000E-03 2.325E-06 1.606E-06
†
 1.734E-06
†
 
No EpCAM 
 
2.800E-03 2.630E-02 1.050E-02 1.280E-02 
Colo205 
Stamped EpCAM 
  
2.683E-06
* 
1.373E-06
†
 1.516E-06
†
 
No EpCAM 
   
3.725E-01 4.857E-01 
MDA-MB-435 Stamped EpCAM 
    
8.260E-01
‡
 
*
Compares stamped vs. non-stamped EpCAM areas within each experimental cell lines 
†
Compares experimental cell lines vs. the negative control cell line 
‡
Compares stamped vs. non-stamped EpCAM areas within the negative control cell line 
 
Table 2 shows a significant higher capture number between the number of SkBr3 cells 
captured on the stamped nanoporous silica area in comparison with the number of SkBr3 cells 
captured on non-stamped areas, indicating the feasibility of the method. The ANOVA test 
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comparing the two experimental conditions returned a p-value of 4.589E-5 (Table 3), thereby 
statistically justifying the feasibility of the method. The results of condition 1 are also 
significantly different from that of conditions 5 (MDA-MB-435, stamped EpCAM) and 6 
(MDA-MB-435, no EpCAM), both of which served as negative controls, given MDA-MB-435 is 
an EpCAM negative cell line. This indicates that the SkBr3 cells were truly attracted to the 
stamped nanoporous silica surface mostly due to anti-EpCAM antibody-EpCAM antigen 
interactions and not simply adhering to the surface by means of other physical mechanisms.   
Table 2 also shows a significant higher capture number between the number of Colo205 
cells captured on the stamped nanoporous silica area in comparison with the number of Colo205 
cells captured on non-stamped areas, again demonstrating the feasibility of the method. The 
ANOVA test comparing the two experimental conditions returned a p-value of 2.683E-6 (Table 
3), again statistically justifying the feasibility of the method. Like condition 1 (SkBr3, stamped 
EpCAM), condition 3 (Colo205, stamped) also exhibited a significantly higher capture number 
in comparison to conditions 5 and 6. All results obtained from Tukey’s Method were consistent 
with the group-by-group ANOVA comparisons shown in Table 3. 
Variability in capture cell numbers across different cell lines can be attributed the 
biological differences between cell lines in biomarker expression. Various factors such as stage 
in cellular growth and development, cell health, and cell type contribute to the concentration and 
amount of expression of a particular biomarker on a cell’s surface. Additional non-specific cell 
binding on the substrate surface may be due to the high density of cells used. In addition, 
physical contact between cells and surface and the porous nature of the silica thin film may serve 
to enhance mechanical attraction effects of cells to substrate. It has been shown that design 
alterations made to increase capture efficiencies can result in increase of non-specific binding as 
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well. As discussed in [77], this tradeoff is recognized and therefore balanced based on the 
intended device application, which in this case is the acquisition of targeted cells in specifically 
antibody defined locations, is made. Fluorescence immunoassay as a final step is also important 
and necessary to verify the detection and capture of the cell of interest, and can be seen used in 
other CTC screening chips that deal with complex samples and experience a number of non-
specific bindings (white blood cells), as a supporting validation step [69, 70, 73]. 
 
5.3 Conclusion 
In this section of the thesis, a method for the capture and detection of QD-labeled cancer 
cells on a surface was described. The system utilized the advantages of the spatially controlled 
large-scale patterning of microcontact printing and the enhanced absorption of antibodies of the 
nanoporous silica thin film substrates. The experiments described in the previous sections 
demonstrated proof of concept. Cancer cells were indeed successfully captured in areas of 
microcontact printed anti-EpCAM. Statistical analysis confirmed a significant difference 
between experimental and control conditions. It was also shown that the microchip has the 
specificity to differentiate EpCAM positive cells from EpCAM negative cells. This part of the 
thesis validated the capture of cancer cells within microcontact printed areas of antibodies in a 
static environment. This provides the foundation for the following part of the thesis, in which the 
microchip system is integrated with a microfluidic channel for enhanced site-specific targeted 
cancer cell capture.  
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6 Site-Specific Cancer Cell Detection in Microfluidics  
This section of the thesis combines all the advantages of microcontact printed nanoporous 
silica substrates, QDs, with those of microfluidic channels into a wholesome integrated 
microchip-based cancer cell detection platform. With all elements combined, effective and 
efficient enhancement of the capture, detection, and imaging of cancer cells can be performed. 
This integration also uniquely allows for site-specific targeted cancer cell capture catered to 
particular microchannel geometries. Ultimately, such a platform can be designed to perform rare 
cell screening and detection for applications in cancer detection and diagnostics. 
6.1 Experimental Methods 
6.1.1 Microfluidic Modeling 
 
To demonstrate microfluidic enhancement of cell capture, a design example was used. 
Here, a microfluidic channel of 20 mm long and 200 µm high was constructed with two grooves, 
each 5 mm wide, 100 µm deep, and spaced 3 mm apart from each other. The first groove was 
placed 1 mm away from the channel inlet. The inlet and outlet were modeled as two 50 µm wide 
by 200 µm high rectangles at the edges of the channel. A schematic of the microfluidic channel 
is shown in Figure 24. 
 The proposed grooved microchannel was modeled in COMSOL Multiphysics 4.2 to 
determine optimal locations for cell-surface interactions. Laminar flow at the walls was set to a 
no slip boundary condition. Flow at the inlet was set to a 0 Pa pressure and no viscous stress 
boundary condition. Flow at the outlet was set to a laminar outflow rate of 0.04 mL/s boundary 
condition. A free triangular mesh was constructed and scaled by a factor of 10 in the y-direction 
to capture more data points in the y-direction. The resulting velocity models were captured and 
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plotted for three solution sets: velocity 
magnitude, y-component velocity field, 
and x-component velocity field.  
By determining optimal locations 
for cell-surface interactions within the 
microchannel through computer 
simulated models, controlled large-scale 
patterning of antibodies can be achieved 
for cancer cell capture at targeted specific 
areas on the substrate surface. 
6.1.2 Site-Specific Cancer Cell Capture 
 
 
A thin film plastic mold constructed from 100 µm thick plastic was used to create the 
grooved microchannels. The PDMS microchannels were fabricated in the same fashion as the 
PDMS stamps were fabricated, as described earlier (Section 5.1.2). Briefly, a PDMS mixture of 
10:1 polymer to curing agent ratio was thoroughly mixed and desiccated. The mixture was then 
poured into the plastic mold and allowed to cure overnight. 
 Microfluidic experiments were then performed to demonstrate enhanced location-
selective capture of cancer cells. Microcontact printing of anti-EpCAM was performed in a 
similar fashion as previously described in Section 5.1.2. Briefly, 2 mm x 4 mm rectangular 
PDMS stamps were incubated with anti-EpCAM, rinsed, dried, and then manually stamped onto 
the nanoporous silica surface at specific areas along the x-direction found in previously 
generated models (Section 6.1.1), as shown in Figure 25.  After microcontact printing of anti-
Figure 24. Model Microfluidic Channel. (a) Side view of 
the grooved microfluidic channel and its dimensions. (b) 
Image of the grooved PDMS microchannel on nanoporous 
silica substrate with Teflon tubing for inlet and outlet. 
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EpCAM, the prepared PDMS grooved 
microchannels were manually aligned and simply 
bonded directly onto the nanoporous silica 
substrate surface. Immuofluorescence detection 
of QD-labeled SkBr3 cancer cells was also 
performed in a similar fashion as previously 
described (Section 5.2.2). Briefly, a 3 mL SkBr3 
cancer cell in PBS buffer solution (100,000 cells) 
was prepared and incubated with QD625-labeled 
anti-HER2 (50 µg/mL) and FITC-labeled anti-CK (20 µg/mL). Here, we use high cell densities 
to better illustrate the concept of being able to selectively capture cells in optimal areas while 
observing little to no binding of cells in non-optimal areas.   
A syringe pump was used to draw liquid reagents and samples through the grooved 
microchannel at a flow rate of 2.5 mL/hr from a reservoir. A 1 mL 1% BSA (Sigma Aldrich) 
blocking solution was flowed into the microchannel and allowed to sit and incubate for 30 min. 
After the BSA blocking step, PBS (1 mL) was flowed in to rinse the channel and the 
FITC,QD625-labeled SkBr3 cancer cells were introduced into the channel. A final PBS rinse 
was then performed. To fix the captured cells onto the surface of the nanoporous substrate, 1 mL 
of glacial acetone was flowed into and incubated for 10 min in the channel as the channel was 
cooled in an ice bath. The PDMS microchannel was then peeled away from the substrate and the 
nanoporous substrate was placed under the microscope for fluorescence imaging after DAPI 
staining. The number of cells in each of the four test areas was counted along the x-direction (see 
coordinates in Figure 25) in a top to bottom fashion (along the negative y-direction). 
Figure 25. Site Specific Capture. Top view of the 
grooved microfluidic channel and its dimensions. 
Optimal (green dashed lines) and non-optimal 
locations (red dashed lines) for cell-surface 
interaction based on COMSOL and MATLAB 
modeling results are shown. The black boxed areas 
indicate areas of microcontact printed anti-EpCAM 
antibodies. 
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6.1.3 Statistical Analysis 
 
Statistical analysis was performed for the comparison of cell capture numbers between 
anti-EpCAM stamped optimal and nonoptimal areas on the substrate after integration of a 
grooved microfluidic channel. The averages and standard deviations were tabulated for each 
experiment’s data set and the ANOVA test was used to make comparisons. For more detailed 
protocol, refer back to Section 5.1.4. 
6.2 Results and Discussion 
6.2.1 Modeling of the Microchannel 
 
A microchannel 2 cm long and 200 µm high with grooves 5 mm wide and 100 µm deep 
was modeled. The resulting solution sets were plotted in COMSOL and MATLAB. Optimal 
locations along the length of the microchannel for cell-surface interactions were determined by 
plotting the y-component velocity field 0 µm    y   20 µm (see Figure 26). This range of y 
values was chosen to be modeled in order to represent the streamline and velocity behavior of an 
average cancer cell (about 15 µm). Cells in this modeled range are more likely to be captured 
due to physical size and their relative y-position within the microchannel. Therefore, we are 
interested in studying the flow of single cells closest to the substrate surface. From the flow and 
velocity y-component profiles, the optimal location at which a single cell has highest probability 
of interacting with antibodies microcontact printed on the nanoporous silica substrate can be 
determined. Optimal locations can be defined by areas where the most negative Vy occurs, that is, 
at locations along the microchannel where the absolute minimum occurs. Alternatively, non-
optimal locations are defined by areas where the most positive Vy, or the absolute maximum 
occurs. From the plot and data, it was found that three locations along the microchannel were 
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optimal for cell-surface interactions: 3469 µm, 11463 µm, and 19409 µm from the inlet. The 
three least optimal locations were also found: 566 µm, 8561 µm, and 16556 µm from the inlet. 
 
Figure 26 shows an example of an optimal and a non-optimal location along the 
microchannel. The streamlines for flows at y = 0 µm, 5 µm, 10 µm, 15 µm, and 20 µm, as well 
as the corresponding Vy and Vx components are shown. It is understood that free flowing cells at 
heights y > 20 µm, may not experience a force large enough to allow interaction with capture 
antibodies and instead experience a slight dip in trajectory and continue its flow through the 
Figure 26. Microchannel Modeling. The streamlines of flow as well as the theoretical x- and y- velocity fields at 
both (a) non-optimal and (b) optimal locations along the grooved microfluidic channel. The velocity components, Vx 
and Vy, were plotted for y-values of y = 0 µm (♦), 5 µm (--), 10 µm (··), 15 µm (–·), and 20 µm (―). Optimal 
locations along the microchannel occur where Vy is at absolute minimum and should be areas of highest probability 
for cell-surface interactions. 
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channel. However, it can be seen in Figure 26 that y = 20 µm, Vy is about 5% of Vx and 
decreases as y decreases. At optimal locations, a single cell traveling in the trajectories of the 
streamlines within the range 0 µm ≤  y  ≤ 20 µm, will have higher probability of interacting with 
capture antibodies at the surface of the nanoporous silica substrate than at non-optimal locations. 
This is because cells flowing through optimal locations, carried by fluid, will experience a larger 
downward velocity that generates a force which pushes the cell towards the capture antibodies 
stamped on the nanoporous silica surface. 
6.2.2 Microfluidic Integration 
 
To verify the feasibility of targeted spatial cancer cell capture, a grooved microfluidic 
channel was fabricated and integrated with a microcontact printed nanoporous silica substrate. 
As described earlier (Section 6.1.2), selected areas located at both optimal and non-optimal 
locations along the x-direction were stamped with anti-EpCAM. It is expected that areas with 
largest negative y-component velocity vector will observe higher cell capture than areas with 
largest positive y-component velocity vector. In addition, by controlling the spatial patterning of 
anti-EpCAM antibodies, we can further optimize cell capture capability by taking advantage of 
both the geometry of the microchannel and the microcontact printed antibodies.  
From the microfluidic experiments, the number of captured SkBr3 cells within each anti-
EpCAM stamped 2 mm x 4 mm nanoporous silica area was counted. It has been shown that 
current technologies for EpCAM based detection enables detection of rare cells down to about 5 
cells/mL of blood [70]. Here, we use higher densities of cell numbers for experimental validation 
of the feasibility of our method and proof of concept. By using larger numbers of cells, we can 
better illustrate and emphasize the difference in numbers of cells selectively captured in optimal 
locations in comparison to the minimal number of cells captured in non-optimal locations. 
 53 | P a g e  
 
It was found that the average number of cells captured in the expected optimal locations 
was 329.8 + 32.3 cells. The average number of cells captured in the expected nonoptimal 
locations was 100 + 12.6 cells. The ANOVA test returned a p-value of 1.130E-5, a value 
significantly less than 0.05, thereby statistically justifying the feasibility of the method and the 
cell capture enhancement through integration of a grooved microfluidic channel on an antibody-
patterned nanoporous silica substrate. Figure 27 contrasts the captured cell density within an 
anti-EpCAM stamped area in an optimal location along the microchannel with the captured cell 
density within an anti-EpCAM stamped area in a nonoptimal location along the microchannel on 
the nanoporous silica substrate. It can be seen that the captured cell density within the expected 
optimal area is higher than that within the expected nonoptimal area.  
Figure 27. Capture Site-Specific Cancer Cell Imaging. Fluorescence microscopy images of captured SkBr3 cells on 
the nanoporous silica substrate from microfluidic experiments. The DAPI images show the captured cell density 
within a stamped anti-EpCAM area of an optimal location along the microchannel and the captured cell density 
within a stamped anti-EpCAM area of a nonoptimal location along the microchannel on the same nanoporous silica 
substrate. 
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6.3 Conclusion 
In this section of the thesis, a method for site specific capture and detection of QD-
labeled cancer cells within a static environment was described. The system utilized the 
advantages of the spatially controlled patterning of microcontact printing and the enhanced 
absorption of antibodies of the nanoporous silica thin film substrates. Most importantly, the 
system also utilized the advantage of a microfluidic channel to increase the probability of cell-
surface interactions. By confining the reagent and sample fluids to a microscale volume within a 
grooved microchannel, a micromixing environment was created and further enhanced the chance 
of binding between the microcontact printed anti-EpCAM on the nanoporous silica substrate and 
the EpCAM biomarkers on the cancer cells’ surface. The experiments described in the previous 
sections demonstrated proof of concept. Cancer cells were indeed successfully captured in areas 
of microcontact printed anti-EpCAM. Statistical analysis confirmed a significant difference 
between experimental and control conditions. This part of the thesis validated the capture of 
cancer cells within specifically defined microcontact printed optimal locations within a grooved 
microfluidic channel.  
It can therefore be seen that the integration of the following micro and nanotechnologies 
and techniques into an integrated microchip-based platform can create an effective and efficient 
system for cancer diagnostics and detection: 1) microcontact printing, 2) nanoporous silica thin 
film substrate, 3) quantum dots, and 3) microfluidic channels. This platform can be further 
developed into a detection system for rare cell detection, especially for CTC detection in whole 
blood. Combined, the technologies allow for specific and selective capture of cancer cells that 
incorporate the additional low cost and high throughput advantages of micro and 
nanotechnologies.  
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7 Closing Remarks and Future Directions 
This thesis presents a description of the design and experimental pathway that was 
undertaken to develop a method for the capture and detection of QD-labeled cancer cells in 
microfluidic chips. Efficient cell capture was achieved on a site-specific microcontact printed 
nanoporous silica substrate via antibody-antigen interactions within a grooved microfluidic 
channel. The method of capture and detection utilizes and optimizes the advantages of four 
components: 1) microcontact printing for quick, easy, and efficient transfer of proteins or 
antibodies, 2) nanoporous silica thin film substrate for enhanced protein absorption and surface 
functionalization, 3) quantum dots for brighter and more stable imaging, and 4) site-specific 
capture sites unique to microfluidic channel geometries to enhance the cell-surface interaction at 
predetermined optimal areas.  
Potential applications for such a system includes high throughput screening, drug assays 
and in vivo diagnostics, site-specific cell culturing, as well as cancer cell biomarker studies. The 
flexibility to spatially define capture sites at optimal locations, in combination with single chip 
integration, microfluidics and QD-labeling, enables further multiplexing and multicolor detection 
capabilities. Multiple cancer cell lines would be able to be detected on the same substrate and 
multicolor labeled biomarkers can be simultaneously detected in such integrated micro total 
analysis systems. As seen throughout this thesis, the integrated platforms show great promise for 
a broad range of biomedical applications.  
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